Tadalafil Aristo Pharma 5mg film-coated tablets Malte - anglais - Medicines Authority

tadalafil aristo pharma 5mg film-coated tablets

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - tadalafil - film-coated tablet - tadalafil 5 mg - urologicals

Tadalafil Aristo Pharma 10mg film-coated tablets Malte - anglais - Medicines Authority

tadalafil aristo pharma 10mg film-coated tablets

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - tadalafil - film-coated tablet - tadalafil 10 mg - urologicals

Tadalafil Aristo Pharma 20mg film-coated tablets Malte - anglais - Medicines Authority

tadalafil aristo pharma 20mg film-coated tablets

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - tadalafil - film-coated tablet - tadalafil 20 mg - urologicals

Melphalan Pharmexon 50 mg powder and solvent for solution for injection/infusion Irlande - anglais - HPRA (Health Products Regulatory Authority)

melphalan pharmexon 50 mg powder and solvent for solution for injection/infusion

pharmexon consulting s.r.o - melphalan hydrocholoride - powder and solvent for solution for injection/infusion - 50 milligram(s) - nitrogen mustard analogues; melphalan

Ceftazidime PharmSol 500 mg Powder for Solution for Injection Malte - anglais - Medicines Authority

ceftazidime pharmsol 500 mg powder for solution for injection

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - powder for solution for injection - ceftazidime pentahydrate 500 milligram(s) - antibacterials for systemic use

Ceftriaxone PharmSol 2 g Powder for Solution for Infusion Malte - anglais - Medicines Authority

ceftriaxone pharmsol 2 g powder for solution for infusion

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftriaxone sodium - powder for solution for infusion - ceftriaxone sodium 2 gram(s) - antibacterials for systemic use

Apixaban Combino Pharm 2.5 mg film-coated tablets Malte - anglais - Medicines Authority

apixaban combino pharm 2.5 mg film-coated tablets

combino pharma (malta) ltd. hf60, hal far industrial estate, bbg07, hal far, malta - apixaban - film-coated tablet - apixaban 2.5 mg - antithrombotic agents

Apixaban Combino Pharm 5 mg film-coated tablets Malte - anglais - Medicines Authority

apixaban combino pharm 5 mg film-coated tablets

combino pharma (malta) ltd. hf60, hal far industrial estate, bbg07, hal far, malta - apixaban - film-coated tablet - apixaban 5 mg - antithrombotic agents

Clopidogrel 1A Pharma Union européenne - anglais - EMA (European Medicines Agency)

clopidogrel 1a pharma

acino pharma gmbh  - clopidogrel - peripheral vascular diseases - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome:- non st segment elevation acute coronary syndrome (unstable angina or non q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.

Clopidogrel Acino Pharma GmbH Union européenne - anglais - EMA (European Medicines Agency)

clopidogrel acino pharma gmbh

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.